Lung Cancer Research

Johns Hopkins has been a leader in lung cancer research for decades. Among the investigations our researchers are pursuing is an inhaled targeted therapy that delivers its anticancer medicine using nanoparticles. Targeted therapy works by attacking only specific cancer cells, as opposed to traditional chemotherapy, which affects many kinds of cells, including healthy ones.

Additionally, in collaboration with the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, we are working on immunotherapy treatments for early-stage, locally advanced and advanced-stage lung cancer. Immunotherapy works by using the body’s own immune system to combat cancer. The National Comprehensive Cancer Network has written consensus guidelines identifying immunotherapy as being more effective than chemotherapy.

Members of our team are also pursuing population-based investigations aimed at improving access to prevention and treatment for all people, including looking at health disparities related to cancer and assessing the outcomes of various health delivery models.